London-based biotech Leucid Bio raises £11.5M funding for hard-to-treat cancers

Leucid Bio Raises £11.5M in Series A Funding

London-based biotech company Leucid Bio has raised £11.5 million in Series A funding to advance its innovative CAR-T cell therapies for challenging cancers. The funding will primarily support the Phase 1 trial of their lead candidate, LEU-011, for platinum-resistant ovarian cancer. LEU-011 is an NKG2D CAR T-cell therapy showing promise in pre-clinical development for various solid tumors and hematological malignancies. Leucid Bio's groundbreaking technology aims to overcome the limitations of current CAR-T therapies in treating solid tumors, offering hope for patients with limited treatment options.

Leucid Bio Secures £11.5M to Advance Next-Gen CAR-T Cell Therapies for Hard-to-Treat Cancers

Leucid Bio is a pioneering biotech company developing next-generation cell therapies for hard-to-treat cancers, especially solid tumors. The company's proprietary engine builds upon Dr. Maher's novel CAR-T model, which develops CAR-T molecules designed to be in a more natural biological configuration of cells. This technology enhances T-cell potency and generates a persistent long-term response with reduced toxicity, aiming to improve treatment outcomes for individuals with hard-to-treat solid tumors.

Leucid Bio develops next-generation cell therapies for hard-to-treat cancers, focusing on solid tumors.

4 years ago

Leucid Bio Secures £11.5M to Advance Next-Gen CAR-T Cell Therapies for Hard-to-Treat Cancers

ProblemHealthcare

Solution

Covered on